Nichi-Iko Set To Delist In March As Tamura Steps Down As CEO

Successor To Be Selected At Extraordinary General Meeting In February

 
• By Chloe Kent

After nearly two difficult years for Nichi-Iko Pharmaceutical, the firm has announced at it will be acquired by a private equity fund and delisted from the Toyko Stock Exchange in 2023 and its CEO will step down from his post.

Word delisting on dark blue finance background
Nichi-Iko is set to be absorbed by a private equity firm • Source: Shutterstock

More from Strategy

More from Business